Attached files
file | filename |
---|---|
8-K - FORM 8-K - R1 RCM INC. | c59745e8vk.htm |
Exhibit 99.1
Accretive Health Reports Financial Results for the Second Quarter of 2010
| 27% Projected Contracted Annual Revenue Run Rate Growth Over Second Quarter 2009 |
| Non-GAAP Adjusted EBITDA of $12.3 million, a 105% Growth Over Second Quarter 2009 | |
| $0.07 Non-GAAP Adjusted Net Income per Diluted Share |
Chicago, IL, August 12, 2010 Accretive Health, Inc. (NYSE: AH), a leading provider of
comprehensive end-to-end healthcare revenue cycle management services, today announced financial
results for the quarter ended June 30, 2010.
Key Financial Results Second Quarter 2010
| Net services revenues for the second quarter of 2010 was $151.9 million, an increase of $26.2 million, or 21% over the second quarter of 2009. |
| Operating margin for the second quarter of 2010 was $33.9 million, an increase of $11.2 million, or 49% over the second quarter of 2009. |
| Income from operations for the second quarter of 2010 was $7.4 million, an increase of $4.5 million, or 155% over the second quarter of 2009. |
| Net income attributable to common shareholders for the second quarter of 2010 was $3.9 million, an increase of $1.3 million, or 48% over the second quarter of 2009. |
| Non-GAAP adjusted EBITDA was $12.3 million for the second quarter of 2010, an increase of $6.3 million, or 105% over the second quarter of 2009. |
| Non-GAAP adjusted net income per diluted common share was $0.07 for the quarter ended June 30, 2010. |
| Diluted earnings per common share was $0.04 for the quarter ended June 30, 2010. |
| The Companys projected contracted annual revenue run rate at June 30, 2010 was $614 million to $626 million compared to $483 million to $493 million at June 30, 2009. The midpoint of the range at June 30, 2010 increased by $132 million, or 27%, from the midpoint of the range at June 30, 2009. |
Mary Tolan, Accretive Healths Co-Founder and Chief Executive Officer said, We are very pleased
with our results for the second quarter, our continuing top-line growth, our margin expansion and
our increasing profitability. These results are driven by the increasing level of value we deliver
to our customers through both net revenue yield improvements and operating efficiencies.
We are also pleased with the notable increase we are seeing in our existing customers interest in
adopting our shared services operating model. We are presently in detailed discussions concerning
the transition of multiple existing customers revenue cycle operations into our shared services.
We expect these transitions to begin in the coming quarters. These adoptions could increase the
use of our shared services model from 33% of our current revenue mix to 52% of our current revenue
mix. We do expect that this will lead to a slight reduction of future net base fee revenues as we
share with our customers a portion of the incremental cost savings achieved after the transition is
complete. However, these upcoming adoptions would represent a positive development as our profit
margins improve as customers begin using our shared services operating model.
Net Services Revenue Second Quarter 2010
Total net services revenue for the second quarter of 2010 grew 21% to $151.9 million from $125.7
million in the second quarter of 2009. Base fee revenues were $128.2 million during the second
quarter, a 21% increase over the second quarter of 2009. Incentive payments were $20.1 million
during the second
1
quarter, a 21% increase over the second quarter of 2009. Other services revenue was $3.6 million
during the second quarter.
The base fee component of net services revenue for the quarter ended June 30, 2010 would have been
greater except for the lower than anticipated inflation adjustments in both base fees and the
associated hospital employee labor costs. Base fees typically increase annually due to an
inflation factor that is highly correlated with the actual payroll increases implemented across our
customers hospitals. The impact to second quarter 2010 revenue of the lower than expected
inflation adjustment is estimated at $2.2 million. This trend has virtually no impact on income
from operations, net income, and non-GAAP adjusted EBITDA, as base fees and unit labor costs move
together.
The companys projected contracted annual run rate of revenue at June 30, 2010 increased by
approximately 27% from the June 30, 2009 projection based on the mid-points of the respective
ranges. The majority of the increase in the contracted annual revenue run rate reflects the
increase in the number of healthcare providers for whom Accretive is providing revenue cycle
management services from 53 at June 30, 2009 to 61 at June 30, 2010.
Non-GAAP Adjusted EBITDA and Adjusted Net Income
Increased incentive fee payments in the second quarter of 2010 combined with increasing operating
cost efficiency allowed the company to more than double its adjusted EBITDA to $12.3 million for
the quarter ended June 30, 2010 from $6.0 million for the quarter ended June 30, 2009. Non-GAAP
adjusted net income in the second quarter of 2010 was $6.1 million, an increase of $2.1 million, or
55% over the prior year quarter.
2010 Outlook
Management estimates that the companys projected contracted annual run rate of revenue at the end
of 2010 will exceed $710 million, an increase of at least 38% from the $510 million to $519 million
(midpoint of $514 million) projected contracted annual revenue run rate at the end of 2009. The
companys ability to exceed $710 million in projected contracted annual revenue run rate at
December 31, 2010 will depend on the timing and success in closing the current strong pipeline of
customer opportunities. Management also expects that full year 2010 non-GAAP adjusted EBITDA will
be $43 million to $46 million.
Conference Call
Accretive Healths management will host a conference call beginning at 7:30 A.M. Central Time on
August 12, 2010 to discuss the companys second quarter 2010 results and business outlook. To
participate, callers can dial 1 (888) 679-8038 from within the U.S. or 1 (617) 213-4850 from any
other country. Thereafter, callers will be prompted to enter the participant pass-code, 69022837.
For those who cannot participate in the call, a replay will be available on Accretive Healths
website, www.accretivehealth.com, after the end of the call.
About Accretive Health
Accretive Health is a leading provider of healthcare revenue cycle management services. Our
business purpose is to help U.S. hospitals, physicians and other healthcare providers manage their
revenue cycle operations more efficiently. Our integrated technology and services offering, which
we refer to as our solution, helps our customers realize sustainable improvements in their
operating margins and improve
2
the satisfaction of their patients, physicians and staff. Our customers typically are
multi-hospital systems, including faith-based or community healthcare systems, academic medical
centers and independent ambulatory clinics, and their affiliated physician practice groups. Our
solution spans our customers entire revenue cycle, unlike competing services that we believe
address only a portion of the revenue cycle or focus solely on cost reductions. Through the
implementation of our distinctive operating model that includes people, processes and technology
our customers have historically achieved significant improvements in cash collections measured
against the contractual amount due for healthcare services, which we refer to as net revenue yield.
Safe Harbor
This press release contains forward-looking statements, including statements regarding expectations
for future financial and business performance and market growth, which involve risks and
uncertainties. Our actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors, including those set forth in our
Prospectus filed pursuant to Rule 424(b)(4) and contained in the related Registration Statement on
Form S-1 declared effective by the SEC on May 20, 2010 (File No. 333-162186), under the heading
Risk Factors. The words anticipates, believes, estimates, expects, intends, may,
plans, projects, would, and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. We have
based these forward-looking statements on our current expectations and projections about future
events. Although we believe that the expectations underlying any of our forward-looking statements
are reasonable, these expectations may prove to be incorrect and all of these statements are
subject to risks and uncertainties. Should one or more of these risks and uncertainties
materialize, or should underlying assumptions, projections, or expectations prove incorrect, actual
results, performance, or financial condition may vary materially and adversely from those
anticipated, estimated, or expected.
All forward-looking statements included in this report are expressly qualified in their entirety by
the foregoing cautionary statements. We wish to caution readers not to place undue reliance on any
forward-looking statement that speaks only as of the date made and to recognize that
forward-looking statements are predictions of future results, which may not occur as anticipated.
Actual results could differ materially from those anticipated in the forward-looking statements and
from historical results, due to the uncertainties and factors described above, as well as others
that we may consider immaterial or do not anticipate at this time. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. Our expectations reflected in our forward-looking statements can
be affected by inaccurate assumptions we might make or by known or unknown uncertainties and
factors, including those described above. The risks and uncertainties described above are not
exclusive, and further information concerning us and our business, including factors that
potentially could materially affect our financial results or condition, may emerge from time to
time. We assume no, and we specifically disclaim any, obligation to update, amend, or clarify
forward-looking statements to reflect actual results or changes in factors or assumptions affecting
such forward-looking statements. We advise you, however, to consult any further disclosures we make
on related subjects in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q , and Current
Reports on Form 8-K that we file with or furnish to the U.S. Securities and Exchange Commission.
3
Accretive Health, Inc.
Consolidated Income Statements (Unaudited)
Consolidated Income Statements (Unaudited)
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
( In thousands, except share and per share amounts) | ||||||||||||||||
Net services revenue (1) |
$ | 151,905 | $ | 125,682 | $ | 277,841 | $ | 238,149 | ||||||||
Costs of services |
118,014 | 102,964 | 220,302 | 195,667 | ||||||||||||
Operating margin |
33,891 | 22,718 | 57,539 | 42,482 | ||||||||||||
Other operating expenses: |
||||||||||||||||
Infused management and technology |
16,148 | 13,307 | 31,057 | 24,482 | ||||||||||||
Selling, general, and administrative |
10,309 | 6,492 | 17,877 | 15,308 | ||||||||||||
Total operating expenses |
26,457 | 19,799 | 48,934 | 39,790 | ||||||||||||
Income from operations |
7,434 | 2,919 | 8,605 | 2,692 | ||||||||||||
Interest income |
2 | 39 | 10 | 83 | ||||||||||||
Net income before provision for income taxes |
7,436 | 2,958 | 8,615 | 2,775 | ||||||||||||
Provision for (benefit from) income taxes |
3,517 | (2,893 | ) | 4,383 | (2,439 | ) | ||||||||||
Net income |
$ | 3,919 | 5,851 | $ | 4,232 | 5,214 | ||||||||||
Net income applicable to common shareholders |
$ | 3,919 | $ | 2,647 | $ | 4,232 | $ | 2,356 | ||||||||
Net income per common share (2) |
||||||||||||||||
Basic |
$ | 0.06 | $ | 0.07 | $ | 0.09 | $ | 0.06 | ||||||||
Diluted |
0.04 | 0.06 | 0.05 | 0.05 | ||||||||||||
Weighted average shares used in calculating net income
per common share |
||||||||||||||||
Basic |
61,660,729 | 36,685,057 | 49,642,701 | 36,604,223 | ||||||||||||
Diluted |
92,734,255 | 44,141,368 | 90,734,198 | 45,051,172 | ||||||||||||
(1) The components of net services revenue were: |
||||||||||||||||
Net base fees for managed services contracts |
$ | 128,188 | $ | 105,841 | $ | 239,557 | $ | 205,017 | ||||||||
Incentive payments for managed services contracts |
20,075 | 16,602 | 32,408 | 27,018 | ||||||||||||
Other services |
3,642 | 3,239 | 5,876 | 6,114 | ||||||||||||
Total |
$ | 151,905 | $ | 125,682 | $ | 277,841 | $ | 238,149 | ||||||||
(2) | Net income per common share and weighted-average shares used in calculating net income per common share have been restated for all historical periods to reflect the Companys 3.92-for-1 stock split, which occurred in connection with the Companys initial public offering. |
4
Accretive Health, Inc.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
June 30, | December 31, | |||||||
2010 | 2009 | |||||||
(Unaudited) | ||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 119,874 | $ | 43,659 | ||||
Accounts receivable, net of allowance for doubtful accounts of $82 at June 30, 2010 and
December 31, 2009, respectively |
46,570 | 27,519 | ||||||
Prepaid assets |
2,338 | 4,283 | ||||||
Due from related party |
782 | 1,273 | ||||||
Other current assets |
933 | 1,337 | ||||||
Total current assets |
170,497 | 78,071 | ||||||
Deferred income tax |
8,082 | 7,739 | ||||||
Furniture and equipment, net |
15,358 | 12,901 | ||||||
Goodwill |
1,468 | 1,468 | ||||||
Other, net |
1,098 | 3,293 | ||||||
Total assets |
$ | 196,503 | $ | 103,472 | ||||
Liabilities and stockholders equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 15,769 | $ | 11,967 | ||||
Accrued service costs |
34,000 | 27,742 | ||||||
Accrued compensation and benefits |
8,239 | 12,114 | ||||||
Deferred income tax |
4,154 | 4,188 | ||||||
Accrued income taxes |
1,372 | 41 | ||||||
Other accrued expenses |
4,867 | 3,531 | ||||||
Deferred revenue |
16,662 | 22,610 | ||||||
Current liabilities |
85,063 | 82,193 | ||||||
Non-current liabilities |
||||||||
Other non-current liabilities |
852 | | ||||||
Non-current liabilities |
852 | | ||||||
Total liabilities |
85,915 | 82,193 | ||||||
Commitments and contingencies |
| | ||||||
Stockholders equity: |
||||||||
Convertible preferred stock, Series A, $0.01 par value, no shares authorized, issued and
outstanding at June 30, 2010; 32,317 authorized, issued and outstanding at December
31, 2009 |
| | ||||||
Convertible preferred stock, Series D, $0.01 par value, no shares authorized, issued and
outstanding at June 30, 2010; 1,267,224 shares authorized, issued and outstanding at
December 31, 2009 |
| 13 | ||||||
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or
outstanding at June 30, 2010; no shares authorized, issued and outstanding at December
31, 2009 |
| | ||||||
Series B common stock, $0.01 par value, no shares authorized, issued and outstanding at
June 30, 2010; 68,600,000 shares authorized, 32,156,932 issued and outstanding at
December 31, 2009 |
| 82 | ||||||
Series C common stock, $0.01 par value, no shares authorized, issued and outstanding at
June 30, 2010; 31,360,000 shares authorized, 5,257,727 issued and outstanding at
December 31, 2009 |
| 13 | ||||||
Common stock, $0.01 par value, 500,000,000 shares authorized, 91,062,067 shares
issued and outstanding at June 30, 2010; no shares authorized, issued and outstanding at
December 31, 2009 |
911 | | ||||||
Additional paid-in capital |
136,067 | 51,777 | ||||||
Non-executive employee loans for stock option exercises |
(65 | ) | (120 | ) | ||||
Accumulated deficit |
(26,220 | ) | (30,452 | ) | ||||
Cumulative translation adjustment |
(105 | ) | (34 | ) | ||||
Total stockholders equity |
110,588 | 21,279 | ||||||
Total liabilities and stockholders equity |
$ | 196,503 | $ | 103,472 | ||||
5
Accretive Health, Inc.
Consolidated Statements of Cash Flow (Unaudited)
Consolidated Statements of Cash Flow (Unaudited)
Six Months Ended | ||||||||
June 30, | ||||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Operating activities: |
||||||||
Net income |
$ | 4,232 | $ | 5,214 | ||||
Adjustments to reconcile net income to net cash
used in operations: |
||||||||
Depreciation and amortization |
2,562 | 1,882 | ||||||
Employee stock based compensation |
5,542 | 2,977 | ||||||
Expense associated with the issuance of stock warrants |
| 4,107 | ||||||
Deferred income taxes |
(2,277 | ) | (2,648 | ) | ||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(19,051 | ) | (20,669 | ) | ||||
Prepaid and other current assets |
2,831 | (6,625 | ) | |||||
Accounts payable |
3,795 | 6,587 | ||||||
Accrued service costs |
6,258 | 7,747 | ||||||
Accrued compensation and benefits |
(3,881 | ) | (4,053 | ) | ||||
Other accrued expenses |
1,413 | (1,096 | ) | |||||
Accrued income taxes |
1,333 | (984 | ) | |||||
Deferred rent expense |
852 | | ||||||
Deferred revenue |
(5,948 | ) | (3,510 | ) | ||||
Net cash used in operating activities |
(2,339 | ) | (11,071 | ) | ||||
Investing activities: |
||||||||
Purchases of furniture and equipment |
(2,357 | ) | (1,037 | ) | ||||
Acquisition of software |
(2,646 | ) | (1,790 | ) | ||||
Collection (issuance) of note receivable |
(757 | ) | 444 | |||||
Net cash used in investing activities |
(5,760 | ) | (2,383 | ) | ||||
Financing activities: |
||||||||
Proceeds from the initial public offering, net of issuance costs |
83,756 | | ||||||
Liquidation preference payment |
(866 | ) | | |||||
Proceeds from issuance of common stock from employee
stock option exercise |
166 | 151 | ||||||
Collection (issuance) of non-executive employee notes receivable |
55 | 33 | ||||||
Excess tax benefits from equity-based awards |
1,284 | | ||||||
Deferred offering costs |
| (582 | ) | |||||
Net cash (used in) provided by financing activities |
84,395 | (398 | ) | |||||
Effect of exchange rate changes in cash |
(81 | ) | (15 | ) | ||||
Net increase (decrease) in cash and cash equivalents |
76,215 | (13,867 | ) | |||||
Cash and cash equivalents at beginning of the period |
43,659 | 51,656 | ||||||
Cash and cash equivalents at end of the period |
$ | 119,874 | $ | 37,789 | ||||
6
Explanation of Operational Metrics
We define our projected contracted annual revenue run rate as the expected total net services
revenue for the subsequent twelve (12) months for all healthcare providers for which we are
providing revenue cycle management services that are under contract as of the end of the reporting
period.
Explanation and Use of Non-GAAP Financial Measures
To provide investors with greater insight and a better understanding of how our management and
board of directors analyze our financial performance and make operational decisions, we supplement
our consolidated financial statements that are presented on a GAAP basis in this press release with
the following non-GAAP financial measures: adjusted EBITDA, adjusted net income, and adjusted net
income per diluted common share.
These non-GAAP financial measures should not be considered in isolation; they are in addition to,
and are not a substitution, for financial performance measures under GAAP. These non-GAAP
financial measures may be different from non-GAAP measures used by other companies. Further, we
may utilize other measures to illustrate performance in the future. Non-GAAP measures have
limitations since they do not reflect all of the amounts associated with the Companys results of
operations as determined in accordance with GAAP.
We define non-GAAP adjusted EBITDA as net income (loss) before net interest income (expense),
income tax expense (benefit), depreciation and amortization expense and share based compensation
expense. We define non-GAAP adjusted net income as net income (loss) before share based
compensation expense, net of the estimated tax impact of such expense. We define non-GAAP adjusted
net income per diluted common share as non-GAAP adjusted net income applicable to common
shareholders divided by the weighted average fully diluted common shares outstanding during the
period as computed in accordance with GAAP.
We use non-GAAP adjusted EBITDA:
| as a measure of operating performance, because it does not include the impact of items that we do not consider indicative of our core operating performance; | ||
| for planning purposes, including the preparation of our annual operating budget; | ||
| to allocate resources to enhance the financial performance of our business; | ||
| to evaluate the effectiveness of our business strategies; and | ||
| in communications with our board of directors and investors concerning our financial performance. |
We believe that non-GAAP adjusted EBITDA, non-GAAP adjusted net income, and non-GAAP adjusted net
income per diluted common share are useful to investors in evaluating our operating performance for
the following reasons:
| these and similar non-GAAP measures are widely used by investors to measure a companys operating performance without regard to items that can vary substantially from company to company depending upon financing and accounting methods, book values of assets, capital structures and the methods by which assets were acquired; |
7
| securities analysts often use these and similar non-GAAP measures as supplemental measures to evaluate the overall operating performance of companies; and | ||
| by comparing our non-GAAP adjusted EBITDA in different historical periods, our investors can evaluate our operating results without the additional variations of interest income (expense), income tax expense (benefit), depreciation and amortization expense and share-based compensation expense. |
We understand that, although measures similar to non-GAAP adjusted EBITDA and non-GAAP adjusted net
income are frequently used by investors and securities analysts in their evaluation of companies,
these measures have limitations as an analytical tool, and you should not consider them in
isolation or as a substitute for analysis of our results of operations as reported under GAAP. Some
of the limitations of these specific non-GAAP financial measures are:
| non-GAAP adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or other contractual commitments; | ||
| non-GAAP adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; | ||
| non-GAAP adjusted EBITDA and non-GAAP adjusted net income do not reflect share-based compensation expense; | ||
| non-GAAP adjusted EBITDA does not reflect cash requirements for income taxes; | ||
| non-GAAP adjusted EBITDA does not reflect net interest income (expense); | ||
| although depreciation and amortization are non-cash charges, the assets being depreciated or amortized will often have to be replaced in the future, and non-GAAP adjusted EBITDA does not reflect any cash requirements for these replacements |
Non-GAAP Adjusted EBITDA
The following table presents a reconciliation of non-GAAP adjusted EBITDA to net income, the most
comparable GAAP measure (unaudited; in thousands):
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
Net income |
$ | 3,919 | $ | 5,851 | $ | 4,232 | $ | 5,214 | ||||||||
Net interest income (a) |
(2 | ) | (39 | ) | (10 | ) | (83 | ) | ||||||||
Provision (benefit) for income taxes |
3,517 | (2,893 | ) | 4,383 | (2,439 | ) | ||||||||||
Depreciation and amortization expense |
1,309 | 962 | 2,562 | 1,882 | ||||||||||||
EBITDA |
8,743 | 3,881 | 11,167 | 4,574 | ||||||||||||
Stock compensation expense (b) |
3,590 | 1,519 | 5,542 | 2,977 | ||||||||||||
Stock warrant expense (b) |
| 613 | | 4,107 | ||||||||||||
Non-GAAP Adjusted EBITDA |
$ | 12,333 | $ | 6,013 | $ | 16,709 | $ | 11,658 | ||||||||
(a) | Net interest income represents earnings from our cash and cash equivalents. No debt or other interest-bearing obligations were outstanding during any of the periods presented. | |
(b) | Stock compensation expense and stock warrant expense collectively represent the share-based compensation expense reflected in our financial statements. Of the amounts presented above, $0.6 million and $1.3 million were classified as a reduction in gross revenue for the three and six months ended June 30, 2009, respectively. No such reduction was recorded for the three or six |
8
months ended June 30, 2010 as all available warrants had been previously earned and, therefore, there was no stock warrant expense. |
Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Net Income per Diluted Common Share
The following table presents a reconciliation of non-GAAP adjusted net income to net income, the
most comparable GAAP measure, details how we calculate non-GAAP adjusted net income per diluted
common share, and reconciles non-GAAP adjusted net income per diluted common share to fully diluted
earnings per common share, the most comparable GAAP measure (unaudited; in thousands, except share
and per share amounts):
Non-GAAP
Adjusted Net Income
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
GAAP net income per common share |
$ | 3,919 | $ | 2,647 | $ | 4,232 | $ | 2,356 | ||||||||
Add: Share based expense (a) |
3,590 | 2,132 | 5,542 | 7,084 | ||||||||||||
Less: Tax impact of share based expense (b) |
1,436 | 853 | 2,217 | 2,834 | ||||||||||||
Non-GAAP adjusted net income |
$ | 6,073 | $ | 3,926 | $ | 7,557 | $ | 6,606 | ||||||||
Weighted average common shares, diluted |
92,734,255 | 44,141,368 | 90,734,198 | 45,051,172 | ||||||||||||
Non-GAAP adjusted net income per diluted pro forma common share |
$ | 0.07 | $ | 0.09 | $ | 0.08 | $ | 0.15 | ||||||||
Non-GAAP Adjusted Net Income per Diluted Share
GAAP fully diluted earnings per common share |
$ | 0.04 | $ | 0.06 | $ | 0.05 | $ | 0.05 | ||||||||
Add: Share based expense (a) |
$ | 0.04 | $ | 0.05 | $ | 0.06 | $ | 0.16 | ||||||||
Less: Tax impact of share based expense (b) |
$ | 0.01 | $ | 0.02 | $ | 0.03 | $ | 0.06 | ||||||||
Non GAAP adjusted net income per pro forma diluted common share |
0.07 | 0.09 | 0.08 | 0.15 | ||||||||||||
(a) | Share based compensation is the sum of stock compensation and stock warrant expense in the above reconciliation of non-GAAP adjusted EBITDA. | |
(b) | Tax impact calculated using an effective tax rate of 40% which excludes the impact of state taxes on gross receipts. |
Accretive Health, Inc.
Gary Rubin, Senior Director of Finance, 312-324-7820
investorrelations@accretivehealth.com
Gary Rubin, Senior Director of Finance, 312-324-7820
investorrelations@accretivehealth.com
9